NasdaqGS - Delayed Quote USD

Lexicon Pharmaceuticals, Inc. (LXRX)

1.6000

-0.0100

(-0.62%)

At close: April 24 at 4:00 PM EDT

Currency in USD All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

1,204.0000

139.0000

298.0000

23,995.0000

Cost of Revenue

85.0000

1,929.0000

Gross Profit

1,119.0000

139.0000

298.0000

22,066.0000

Operating Expense

172,869.0000

100,899.0000

87,388.0000

200,851.0000

Operating Income

-171,750.0000

-100,760.0000

-87,090.0000

-178,785.0000

Net Non Operating Interest Income Expense

-5,369.0000

-1,184.0000

-668.0000

-11,777.0000

Other Income Expense

131,988.0000

Pretax Income

-177,119.0000

-101,944.0000

-87,758.0000

-58,574.0000

Net Income Common Stockholders

-177,119.0000

-101,944.0000

-87,758.0000

-58,574.0000

Diluted NI Available to Com Stockholders

-177,119.0000

-101,944.0000

-87,758.0000

-58,574.0000

Basic EPS

-0.80

-0.62

-0.60

-0.53

Diluted EPS

-0.80

-0.62

-0.60

-0.53

Basic Average Shares

221,130.0000

165,733.0000

145,652.0000

110,841.0000

Diluted Average Shares

221,130.0000

165,733.0000

145,652.0000

110,841.0000

Total Operating Income as Reported

-171,750.0000

-100,760.0000

-87,090.0000

-47,800.0000

Total Expenses

172,954.0000

100,899.0000

87,388.0000

202,780.0000

Net Income from Continuing & Discontinued Operation

-177,119.0000

-101,944.0000

-87,758.0000

-58,574.0000

Normalized Income

-177,119.0000

-101,944.0000

-87,758.0000

-190,562.0000

Interest Income

7,732.0000

1,596.0000

134.0000

2,767.0000

Interest Expense

13,101.0000

2,780.0000

802.0000

14,544.0000

Net Interest Income

-5,369.0000

-1,184.0000

-668.0000

-11,777.0000

EBIT

-164,018.0000

-99,164.0000

-86,956.0000

-44,030.0000

EBITDA

-163,464.0000

-98,737.0000

-86,664.0000

-41,096.0000

Reconciled Cost of Revenue

85.0000

1,929.0000

Reconciled Depreciation

554.0000

427.0000

292.0000

2,934.0000

Net Income from Continuing Operation Net Minority Interest

-177,119.0000

-101,944.0000

-87,758.0000

-58,574.0000

Total Unusual Items Excluding Goodwill

131,988.0000

Total Unusual Items

131,988.0000

Normalized EBITDA

-163,464.0000

-98,737.0000

-86,664.0000

-173,084.0000

12/31/2020 - 4/7/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

AXSM Axsome Therapeutics, Inc.

71.17

-2.61%

MCRB Seres Therapeutics, Inc.

0.7295

-4.01%

IOVA Iovance Biotherapeutics, Inc.

11.71

-1.26%

VNDA Vanda Pharmaceuticals Inc.

4.5600

-1.51%

ANVS Annovis Bio, Inc.

12.74

+7.24%

CDTX Cidara Therapeutics, Inc.

12.29

+19.90%

RIGL Rigel Pharmaceuticals, Inc.

1.1250

-1.32%

IBRX ImmunityBio, Inc.

4.8200

-12.20%

ABEO Abeona Therapeutics Inc.

3.1700

-7.04%

AKBA Akebia Therapeutics, Inc.

1.3700

0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lexicon Pharmaceuticals, Inc. (LXRX)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers